Biogen rises as FDA clears higher-dose Spinraza for muscle disease

Biogen

30/03/2026 13:48

** Shares of drugmaker Biogen BIIB.O rise 1.75% to $187.06 premarket

** Co says the FDA approved a higher-dose version of Spinraza to treat spinal muscular atrophy, a rare genetic disease that causes severe muscle weakness and can be fatal

** The new dosing can be used in both new patients and those already on Spinraza, co says

** Says approval was based on a late-stage study showing infants had better movement and motor function than untreated patients, with overall safety similar to the older dose

** Co says the high-dose version is already approved in the EU, Switzerland and Japan, and will launch in the U.S. in coming weeks

** Shares rose ~15% in 2025

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))